Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McIntosh H. The clinical and cost-effectiveness of radiofrequency ablation for lung cancer. Glasgow: Healthcare Improvement Scotland. Technologies scoping report 10. 2012 Authors' conclusions Summary
The available evidence on the safety and clinical effectiveness of RFA for primary and secondary lung cancer consists of numerous uncontrolled case series and case reports. Heterogeneity limits the extent to which the data can be synthesised.
A recent systematic review of case series that informed NICE IP guidance on percutaneous RFA concluded that while it was a promising treatment for carefully selected patients, evidence from studies comparing RFA with alternative local treatments was needed. NICE stipulated that patient selection should be carried out by a MDT, and encouraged further research clearly describing case mix and lesion size, and reporting long-term survival.
No evidence was identified on the cost effectiveness of RFA for the treatment of primary or secondary lung cancer in the United Kingdom. A cost-utility analysis in the USA concluded that, if SBRT were not available, RFA could be a more cost-effective treatment than 3D-CRT for small (2 cm), but not larger, tumours in patients with medically-inoperable peripheral stage I NSCLC (primary lung cancer). Indexing Status Subject indexing assigned by CRD MeSH Catheter Ablations; Lung Neoplasms Language Published English Country of organisation Scotland English summary An English language summary is available. Address for correspondence Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Tel: 0141 225 6998 Email: doreen.pedlar@nhs.net AccessionNumber 32013000482 Date abstract record published 25/06/2013 |